A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group InvestigatorsB G Feagan
London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ont, Canada
N Engl J Med 342:1627-32. 2000
..Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known...
- Transfusion practice in elective orthopaedic surgery
B G Feagan
London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ontario, Canada
Transfus Med 11:87-95. 2001
..If allogeneic transfusion rates are to be reduced, eligible patients should be encouraged to participate in ABD programmes. For patients who are ineligible, other preventative strategies should be introduced...
- Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics
B G Feagan
London Clinical Trials Research Group, London, Canada
Can J Clin Pharmacol 8:188-98. 2001
..Infliximab is recommended for the treatment of active Crohn's disease refractory to conventional drugs, and is the treatment of choice for fistulizing Crohn's disease...
- What do I do in my practice that isn't evidence based?
Brian G Feagan
Department of Medicine, University Hospital London Health Science Center, London, Ontario, Canada
Inflamm Bowel Dis 8:422-5; discussion 426-7. 2002
- The efficacy, safety and acceptance of autologous blood donation as a blood conservation strategy
Brian G Feagan
The University of Western Ontario, London, Ontario, Canada
Vox Sang 83:11-2. 2002
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximabB G Feagan
Department of Medicine, Robarts Research Institute, University of Western Ontario, London, Canada
Aliment Pharmacol Ther 33:541-50. 2011
..Certolizumab pegol, administered either every 2 weeks (q2w) or q4w, maintains efficacy in patients previously failing on the anti-TNF agent infliximab (WELCOME study)...
- CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial
B G Feagan
University of Western Ontario, London, ON, Canada
Aliment Pharmacol Ther 23:617-28. 2006
..More than 50% of patients with Crohn's disease become either steroid resistant or dependent. Accordingly, development of new treatments for steroid-dependent Crohn's disease is a research priority...
- Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol
B G Feagan
Robarts Research Institute, University of Western Ontario, 100 Perth Drive, London, ON, Canada
Aliment Pharmacol Ther 33:1143-51. 2011
..Patient-reported outcomes provide unique perspectives on the impact of chronic disease. It is unknown whether a combination of different instruments might improve sensitivity to clinically relevant changes in health status...
- A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
B G Feagan
The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada
Aliment Pharmacol Ther 21:373-84. 2005
..To evaluate CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for the treatment of corticosteroid-dependent Crohn's disease...
- Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study
B G Feagan
Robarts Research Institute, The University of Western Ontario, London, ON, Canada
Aliment Pharmacol Ther 31:1276-85. 2010
..The effect of certolizumab pegol on employment status and work productivity has not been previously assessed...
- A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
B G Feagan
University of Western Ontario, Robarts Research Institute, London, Canada
Pharmacotherapy 21:89S-94S. 2001
..However, use of the clinical pathway was associated with a 1.7-day reduction in BDPM and fewer admissions of low-risk patients...
Transfusion practices for elective orthopedic surgeryBrian G Feagan
Department of Epidemiology and Biostatistics, London Clinical Trials Research Group, John P. Robarts Research Institute, Ont
CMAJ 166:310-4. 2002
..4% of all cases). INTERPRETATION: The use of blood conservation techniques among hospitals in Canada remains low. Only a minority of eligible patients participated in an autologous blood donation program...
- A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty
Cindy J Wong
Robarts Research Institute, Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada
Transfusion 47:832-41. 2007
..The optimum strategy for reducing allogeneic blood transfusion in patients undergoing total hip joint arthroplasty (THJA) is unknown...
- A review of activity indices and end points for clinical trials in children with Crohn's disease
Anne M Griffiths
Hospital for Sick Children, Toronto, Ontario, Canada
Inflamm Bowel Dis 11:185-96. 2005
....
